Menorrhagia Clinical Trials

Find Menorrhagia Clinical Trials Near You

Incidence and Associated Factors of Abnormal Uterine Bleeding During Menstruation in Chinese Women of Childbearing Age Receiving Various Oral Antithrombotic Regimens After Cardiovascular Surgery: A Prospective Longitudinal Observational Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

This study aims to investigate uterine bleeding during menstruation in women taking antithrombotic medications after cardiac surgery. It will evaluate the proportion of patients with abnormal bleeding, such as heavy menstrual bleeding and prolonged menstrual periods, identify associated risk factors, and determine the characteristics of high-risk female patients.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 49
Healthy Volunteers: f
View:

• Female patients aged 18 to 49 years.

• Underwent cardiovascular surgery at our institution (e.g., coronary artery bypass grafting, heart valve repair/replacement, aortic surgery, congenital heart disease correction, heart transplantation).

• Absence of heavy menstrual bleeding (HMB) or prolonged menstrual bleeding (\> 8 days) during the two consecutive menstrual cycles immediately prior to surgery.

• Experienced at least one complete menstrual bleeding episode within the predefined postoperative follow-up window.

• Receiving postoperative oral antiplatelet therapy (e.g., aspirin, clopidogrel) and/or oral anticoagulant therapy (e.g., rivaroxaban, warfarin).

• Concurrent use or non-use of estrogen/progestin modulation therapy is permitted.

Locations
Other Locations
China
Zhongshan Hospital, Fudan University
RECRUITING
Shanghai
Contact Information
Primary
Dandan Sun, Master's degree
sun.dandan1@zs-hospital.sh.cn
+86 64041990
Time Frame
Start Date: 2026-09-16
Estimated Completion Date: 2027-11-16
Participants
Target number of participants: 1308
Treatments
Women receiving different types of antithrombotic therapy
Related Therapeutic Areas
Sponsors
Leads: Shanghai Zhongshan Hospital

This content was sourced from clinicaltrials.gov